Beyond clinical endpoints: Rethinking ALS drug development through disease biology Read more →
With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’ Read more →
Analysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition Read more →
